The Guardian is launching a new feature and wants to hear from readers who have tried GLP-1 receptor agonists but did not achieve the desired results. These drugs, including Ozempic and Wegovy, have been widely used for weight loss and diabetes management, but not everyone responds. The publication is seeking personal accounts to better understand why these medications fail for some individuals. Readers can share their stories via an online form. Responses may be used in upcoming coverage.
